Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00061633 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

169

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Gram-Positive Bacterial
Abscess
Burns
Cellulitis
Ulcer
Wound Infections

Interventions

DRUG: Telavancin
DRUG: Vancomycin or antistaphylococcal penicillin

Sponsor

Cumberland Pharmaceuticals